Merck Vaccines Performance Data Summary 2005-2008
| |
2008 |
2007 |
2006 |
2005 |
| Number of countries where Merck has committed to no-profit prices for ROTATEQ and GARDASIL |
72 |
72 |
N/A |
N/A |
| Number of low and middle income countries using Merck's vaccines in their public sectors |
16 |
11 |
N/R |
N/R |
| Number of vaccines approved, registered in number of countries |
11 vaccines
in 114 countries |
11 vaccines
in more than 100 countries |
N/R |
N/R |
- Number of doses sold worldwide of ROTATEQ, GARDASIL and MMRII
|
55.9M |
46.5M |
N/R |
N/R |
- In high human development index (HDI) countries
|
52.6M |
44M |
N/R |
N/R |
|
|
3.3M |
1.6M |
N/R |
N/R |
|
|
43,000 |
0 |
N/R |
N/R |
|
|
603,000 |
504,000 |
N/R |
N/R |
| Number of new country registrations of GARDASIL and ROTATEQ globally† (and cumulative to date) |
18 (196) |
72 (178) |
105 (106) |
1 (1) |
|
|
6 (119) |
31 (113) |
81 (82) |
1 (1) |
|
|
11 (51) |
28 (40) |
12 (12) |
0 (0) |
|
|
1 (17) |
11 (16) |
5 (5) |
0 (0) |
|
|
8 (38) |
21 (30) |
9 (9) |
0 (0) |
|
Partnership data:
|
- Merck investment in MVN-A ($US)
|
800,000 |
1M |
400,000 |
400,000 |
- Number of health care professionals trained through MVN-A
|
142 |
97 |
103 |
89 |
- ROTATEQ Access Program (Nicaragua) : total doses of vaccine delivered as 1st, 2nd or 3rd dose (as of 12/31/2008)
|
329,560 |
291,797 |
20,325 |
N/A |
- Total doses of ROTATEQ delivered as 3rd dose (fully vaccinated child) (as of 12/31/2008)
|
106,700 |
87,611 |
0 |
N/A |
- Vaccine coverage (% receiving 3rd dose of ROTATEQ) among Nicaraguan infants. (as of 12/31/2008)
|
81% |
80% |
0 |
N/A |
* GAVI list includes 72 countries that are eligible for funding; this includes countries that are classified as low HDI as well as some countries that are classified as medium HDI. Fifteen UN member countries are not included in the HDI due to lack of data.
† Prior year data have been adjusted due to a change in methodology.
The content on this page was last modified on September 15, 2009.
Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.
